Drugs.com - Clinical Trials

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

London, UK 08 May 2025 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the GLISTEN phase III trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), in adults with cholestatic...

May 12, 2025 - 05:21
 0
GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis
London, UK 08 May 2025 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the GLISTEN phase III trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), in adults with cholestatic...
Read More

Tags:

Previous Article

Potential role for Chinese firm in key UK windfarm attracts government scrutiny

Next Article

Australian Fashion Week cheat sheet: Resort 2026

Related Posts

Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim Starts Phase II Study of BI 158486...

May 12, 2025  0

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025  0

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Boehringer’s New Zongertinib Data Demonstrates Durable ...

May 12, 2025  0